Prior authorization required for autologous HCT

Autologous hematopoietic cell transplantation may be considered medically necessary for primary systemic (light-chain) amyloidosis and is subject to prior authorization consistent with product-specific benefit variations and medical necessity review.

• Obtain prior authorization before scheduling autologous HCT to ensure coverage under the member's specific product.
• Authorization will include medical necessity review per applicable benefit variations.

Authorization and code applicability

Autologous HCT is described as covered when medically necessary while allogeneic HCT is listed as investigational and not covered; obtain authorization and submit the applicable procedure codes for review under the member's benefit.

• Use autologous HCT CPT/procedure codes (e.g., 38213, 38206, 38214, 38207, 38215, 38208, 38232, 38209, 38212) when requesting authorization for covered autologous procedures.
• Do not expect coverage for allogeneic procedure codes (e.g., 38205, 38230, 38240, 38242, S2142, S2150) as these are investigational.

Typical pre-HCT treatment context

Clinical management commonly includes chemotherapy (eg, melphalan and prednisone, combination regimens, proteasome inhibitors such as bortezomib, and newer agents including daratumumab-based regimens); selection of HCT typically follows assessment of response to these therapies and eligibility.

• Document prior systemic therapy and response (eg, melphalan/prednisone, bortezomib, daratumumab combinations) in the authorization request.
• Show that HCT selection follows appropriate assessment of treatment response and transplant eligibility.

Confirm product and benefit applicability

Providers must confirm member benefit applicability and product-specific coverage rules when requesting authorization and submitting claims.

• Verify whether this Capital BlueCross policy applies to the member's program or product (benefit variations, FEP guidance).
• Contact Provider Services or Member Services for questions regarding applicability.

Benefit applicability and regulatory compliance

Document compliance with FDA regulations for human cells and tissues when applicable and note that the policy applies only to certain programs and products administered by Capital BlueCross.

• Ensure documentation reflects applicable regulatory considerations (21 CFR parts 1270 and 1271) for hematopoietic stem cells.
• Indicate the member's product/program to confirm policy applicability (eg, FEP instructions).

Coverage contingent on eligibility and medical necessity

Coverage and payment are contingent on the member's benefit program, eligibility on the date of service, and that the service is medically necessary and appropriate.

• Authorize and bill only after confirming member eligibility and any benefit limitations or exclusions that may apply.
• Final claim processing will follow the member's contract terms.

Allogeneic HCT investigational — likely denials

Requests for allogeneic hematopoietic cell transplantation for primary systemic amyloidosis are likely to be denied because the procedure is considered investigational due to insufficient evidence and high treatment-related mortality.

• Expect denial of authorization requests for allogeneic HCT for primary systemic amyloidosis.
• Provide alternative documentation only if part of a clinical trial or exceptional circumstance; standard coverage is not supported.

Allogeneic transplant investigational — claims handling

Allogeneic hematopoietic cell transplantation to treat primary systemic amyloidosis is investigational and therefore not covered; claims submitted with investigational procedure codes may be denied.

• Do not submit claims expecting coverage for investigational allogeneic procedure codes (38205, 38230, 38240, 38242, S2142, S2150).
• If billed, be prepared for claim denial and appeals should reference the investigational policy stance.

Evaluation requirements — document pretransplant eligibility

Standard pretransplant evaluation and demonstration of medical eligibility are implied; include documentation of eligibility criteria and pretransplant assessment in the prior authorization request.

• Attach clinical evidence of eligibility (eg, organ function, performance status, prior therapy response) to support medical necessity for autologous HCT.
• Document that standard pretransplant evaluations were completed prior to authorization submission.

Center requirements — verify facility eligibility

Center-specific credentialing or volume requirements are not specified in this partial policy; providers should confirm any network or program-specific facility requirements separately.

• If the member's benefit or product requires care at a credentialed center, document facility eligibility when requesting authorization.
• Cross-reference related policies (eg, cord blood policy) if applicable to the service setting.